Mode
Text Size
Log in / Sign up

Non-recommended dosing regimens may be associated with major bleeding in patients treated with DOACsNon-Recommended Dosing May Link to Bleeding in VTE Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that non-recommended dosing may be associated with major bleeding, but evidence is of low certainty.

This meta-analysis evaluates the safety profile of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE), specifically examining how dosing regimens and patient adherence influence major bleeding events. The analysis synthesizes data regarding age, non-recommended dosing regimens, and declining adherence.

The authors report a possible association between non-recommended dosing regimens and major bleeding, though this finding is based on low-certainty evidence. Regarding declining adherence, the evidence for an association with major bleeding is limited and of very low-certainty. No statistically significant association was found between age and major bleeding, though the evidence for this finding is also of very low-certainty.

Several limitations were noted, including the fact that most findings were supported by only single studies. The evidence for non-recommended dosing is low-certainty, while evidence for both age and declining adherence is very low-certainty. Due to these limitations, the findings should be interpreted cautiously. Further validation in larger, high-quality prospective studies is required to establish more definitive clinical conclusions regarding DOAC safety in VTE patients.

How this fits prior evidence

This meta-analysis addresses a gap in understanding how specific management factors, such as dosing and adherence, impact safety in VTE patients treated with DOACs. It builds upon prior evidence showing that DOACs reduce stroke, mortality, and major bleeding risk compared to vitamin K antagonists in hemodialysis patients, and that DOACs are a favorable short-term antithrombotic option after left atrial appendage closure to reduce bleeding risk.

Researchers looked at how certain factors affect patients with venous thromboembolism (VTE) who are taking direct oral anticoagulants (DOACs). These are common medications used to prevent blood clots. The study specifically looked at how age, sticking to the prescribed dose, and staying consistent with medication affected the risk of major bleeding.

The analysis found a possible link between using non-recommended dosing regimens and an increased risk of major bleeding. However, the evidence for this finding is considered low-certainty. Other factors, such as the patient's age or a decline in how often they took their medicine, did not show a clear or strong link to bleeding in this review.

Because much of the data comes from only a few studies, these results should be viewed with caution. The evidence for most of the findings is currently limited or of low certainty. Patients and doctors should use these findings as a starting point for discussion rather than a definitive rule for treatment.

What this means for you:
Non-standard dosing for VTE may link to bleeding, but evidence is currently limited and requires more study.

Common questions

Does a patient's age affect the risk of bleeding on DOACs?

The study found no statistically significant association between a patient's age and the risk of major bleeding while taking direct oral anticoagulants. However, it is important to note that the evidence regarding age is considered very low-certainty because the findings were mostly supported by single studies.

Is it dangerous to use a non-recommended dose of blood thinners?

There is a possible association between using non-recommended dosing regimens and an increased risk of major bleeding. Because this evidence is of low-certainty, it should be interpreted cautiously. You should always speak with your doctor before making any changes to your prescribed dosage.

Does skipping doses or declining adherence increase bleeding risk?

The study found only limited evidence of an association between declining adherence and major bleeding. This finding is considered to have very low-certainty. Because the data is limited, these results are not yet enough to change standard medical practices.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BackgroundDirect oral anticoagulants (DOACs) are commonly prescribed for venous thromboembolism (VTE), but major bleeding (MB) remains an important complication of treatment. Despite their widespread use, systematic evaluations of prognostic factors associated with major bleeding during DOAC treatment remain scarce. To address this gap, we conducted a systematic review to identify prognostic factors associated with major bleeding during DOAC treatment in patients with VTE. This study seeks to enhance the safety and efficacy of anticoagulation therapy for VTE patients.Method and resultsA systematic review and meta-analysis were conducted to search the PubMed and Web of Science databases for studies published before September 18, 2026. The review adhered to predefined inclusion and exclusion criteria to identify studies that investigated risk factors for major bleeding associated with DOAC treatment in patients diagnosed with VTE. Among the evaluated prognostic factors, quantitative pooling was possible only for age, which was reported in two studies; the remaining factors were summarized individually. Low-certainty evidence from a single study suggested a possible association between non-recommended dosing regimens and major bleeding. Evidence regarding declining adherence was also limited and of very low certainty. For age, very low-certainty evidence from the pooled analysis of two studies did not demonstrate a statistically significant association with major bleeding.ConclusionThe available evidence suggests possible associations between several prognostic factors and major bleeding in patients with VTE treated with DOACs; however, most findings are supported by low- or very low-certainty evidence and frequently by single studies. These findings should therefore be interpreted cautiously and require validation in larger, high-quality prospective studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.